gen3009
mAbexperimentalMulti-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 24, 2020 (NCT04358458)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Lymphoma, B-Cell · Phase 1/Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 1/Phase 2
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
Mechanism of action
- Leukocyte antigen CD37Supplementation
CD37 supplementation
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04358458 | Phase 1/Phase 2 (Phase 2) | Mar 24, 2020 | Genmab |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genmab | For profit | 1 | 1 | 1 | 2020 |
1 organizations
Page 1 / 1